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Abstract
Introduction: Inhibiting the enzyme Fatty Acid Synthase (FASN) leads to apoptosis of breast carcinoma cells, and
this is linked to human epidermal growth factor receptor 2 (HER2) signaling pathways in models of simultaneous
expression of FASN and HER2.
Methods: In a xenograft model of breast carcinoma cells that are FASN+ and HER2+, we have characterised the
anticancer activity and the toxicity profile of G28UCM, the lead compound of a novel family of synthetic FASN
inhibitors. In vitro, we analysed the cellular and molecular interactions of combining G28UCM with anti-HER drugs.
Finally, we tested the cytotoxic ability of G28UCM on breast cancer cells resistant to trastuzumab or lapatinib, that
we developed in our laboratory.
Results: In vivo, G28UCM reduced the size of 5 out of 14 established xenografts. In the responding tumours, we
observed inhibition of FASN activity, cleavage of poly-ADPribose polymerase (PARP) and a decrease of p-HER2, p-
protein kinase B (AKT) and p-ERK1/2, which were not observed in the nonresponding tumours. In the G28UCM-
treated animals, no significant toxicities occurred, and weight loss was not observed. In vitro, G28UCM showed
marked synergistic interactions with trastuzumab, lapatinib, erlotinib or gefitinib (but not with cetuximab), which
correlated with increases in apoptosis and with decreases in the activation of HER2, extracellular signal-regulated
kinase (ERK)1/2 and AKT. In trastuzumab-resistant and in lapatinib-resistant breast cancer cells, in which
trastuzumab and lapatinib were not effective, G28UCM retained the anticancer activity observed in the parental
cells.
Conclusions: G28UCM inhibits fatty acid synthase (FASN) activity and the growth of breast carcinoma xenografts in
vivo, and is active in cells with acquired resistance to anti-HER2 drugs, which make it a candidate for further pre-
clinical development.
Introduction
Fatty acid synthase (FASN) is a multifunctional enzyme
that is essential for the endogenous synthesis of long-
chain fatty acids from its precursors acetyl-CoA and
malonil-CoA [1]. Blocking FASN activity causes cyto-
toxicity in human cancer cells overexpressing FASN
[2-13]. The proposed oncogenic properties of FASN
seem to be the result of an increased activation of HER2
and its downstream related phosphoinositide-3 kinase/
protein kinase B (PI3K/AKT) and mitogen-activated
protein kinase/extracellular signal-regulated kinase
(MAPK/ERK1/2) signalling cascades or to the mamma-
lian target of rapamycin protein (mTOR) signaling path-
way [4,5,8,13-20]. FASN can also inhibit the intrinsic
pathway of apoptosis [21] and has been recently pro-
posed as a direct target of p53 family members, includ-
ing p63 and p73 [22]. FASN inhibition may also disrupt
the membrane lipid rafts that anchor HER2 [23]. In the
past, FASN inhibitors with antitumour activity have
been limited by either cross-activation of b-oxidation,
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[9,24-28], or low potency [29,30].
The molecular mechanisms of resistance to anti-HER2
therapies in breast carcinomas have been reviewed
recently [31,32]. These include loss of PTEN [33], pre-
dominance of the p95
HER2 expression [34], mTOR/
PI3K/AKT hyperactivation [35], IGF-IR overexpression
[36], and in vivo conversion of HER2+ to HER2- carci-
noma after neoadjuvant trastuzumab [37]. The limited
experimental evidence available shows that, in cancer
cells, a cross-regulation between FASN and HER2 exists
[3,5], and also that pharmacological blockade of FASN
with C75 can overcome acquired resistance to trastuzu-
mab [38].
We have recently described a novel family of anti-
FASN compounds that exhibit in vitro anticancer activ-
ity, which do not exhibit cross-activation of b-oxidation,
and do not induce weight loss in animals [13]. In the
current study, we have characterised molecularly the in
vivo anticancer activity of G28UCM in a model of
FASN+/HER2+ breast carcinoma. In addition, we have
evaluated the pharmacological interaction of G28UCM
with anti-HER drugs, such as trastuzumab, lapatinib,
erlotinib, gefitinib or cetuximab, at the cellular and
molecular levels. Finally, we report the effect of
G28UCM on breast cancer cells resistant to trastuzumab
or lapatinib. Our data support the study of G28UCM as
a potential therapeutic agent, either alone or in combi-
nation, against in vivo HER2+ tumours that have pro-
gressed on trastuzumab and lapatinib.
Materials and methods
Chemicals, reagents and antibodies
Erlotinib (Tarceva
®), gefitinib (Iressa
®) and lapatinib
(Tyverb
®)w e r ep r o v i d e db yR o c h e( R o c h e ,L o n d o n ,
UK), AstraZeneca (AstraZeneca, London, UK) and Glax-
oSmithKline (GlaxoSmithKline, Middlesex, UK), respec-
tively, and were restored in dimethyl sulfoxide (DMSO),
diluted in culture medium at 1:10,000 and stored at -20°
C. Trastuzumab (Herceptin
®, Hoffmann-La Roche
Pharma, Basel, Switzerland) and cetuximab (Erbitux
®,
Merk-Serono, Darmstadt, Germany), provided by the
Division of Pharmacy of the Catalan Institute of Oncol-
ogy (Girona, Spain), were directly diluted in cell culture
medium at 1:1,000 or 1:10,000 and were stored at 4°C.
EGCG, EDTA, dithiotreitol, acetyl-CoA, malonyl-CoA,
NADPH and 3,4,5-dimethylthiazol-2-yl-2,5-diphenylte-
trazolium bromide (MTT) were purchased from Sigma
(St. Louis, MO, USA). The primary antibody for FASN
immunoblotting was a mouse IgG1 FASN monoclonal
antibody from BD Biosciences Pharmingen (San Diego,
CA, USA). Monoclonal anti-b-actin mouse antibody
(clone AC-15) was from Sigma. Rabbit monoclonal anti-
bodies against mTOR and phospo-mTOR
Ser2448 were
from Cell Signaling Technology (Beverly, MD, USA).
Rabbit polyclonal antibodies against PARP, ERK1/2
(extracellular signal-regulated kinase), phospo-ERK1/2
Thr202/Tyr204, AKT, phospho-AKT
Ser473,a n dm o u s e
monoclonal p185
HER-2/neu were from Cell Signaling
Technology. Peroxidase conjugated secondary antibody
was from Calbiochem (San Diego, CA, USA). 1,3-bis
((3,4,5-thihydroxybenzoil)oxy)naphthalene (G28UCM)
was synthesized as previously described [13].
Cell culture and cell lines
BT474 and AU565 breast carcinoma cells were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD, USA). BT474 cells were cultured in
DMEM-F12 (Gibco, Berlin, Germany) supplemented
with 10% heat-inactivated fetal bovine serum (FBS,
HyClone Laboratories, Logan, Utah, USA), 1% L-gluta-
mine, 1% sodium pyruvate, 50 U/mL penicillin, and 50
μg/mL streptomycin (Gibco). AU565 cells were routi-
n e l yg r o w ni nD u l b e c c o ’s Modified Eagle’sM e d i u m
(DMEM, Gibco) supplemented as above. Trastuzumab-
resistant cells (AU565TR) were developed [39,40] by
exposing AU565 cells continuously to trastuzumab (0.4
μM for pool 0.4 and 2 μM for pool 2) for six months.
Cells per plate were then pooled together and sensitivity
to trastuzumab was determined by treating AU565 par-
ental (AU565WT) and resistant (AU565TR) cells with 2
μM trastuzumab and performing trypan blue exclusion
assay periodically during 10 days. Thus, cell pools which
were resistant to trastuzumab were maintained in 2 μM
trastuzumab, a concentration at which parental cells
were not viable. To develop lapatinib-resistant cells
(AU565LR), AU565 cells were treated for one month
with an initial dose of 3.5 μM of lapatinib (IC40 of lapa-
tinib in AU565WT cells), at which time the dose of
lapatinib was increased up to 7 μMf o rf i v em o n t h s .
AU565LR cells were maintained in 7 μM lapatinib, a
concentration at which AU565 parental cells were not
viable.
Growth inhibition and dose-response studies
Dose-response studies were done using standard colori-
metric MTT reduction assay. Parental AU565 and tras-
tuzumab- and lapatinib-resistant AU565 cells were
p l a t e do u ta tad e n s i t yo f7×1 0
3 cells/100 μL/well in
96-well microtitre plates. Following overnight cell adher-
ence, the medium was removed and fresh medium along
with the corresponding concentrations of FASN inhibi-
tors (EGCG and G28UCM) or anti-HER agents (trastu-
zumab, cetuximab, erlotinib, gefitinib and lapatinib)
were added to the cultures. For the drug-combination
experiments a dose concentration of G28UCM (5 to 40
μM) and EGCG (20 to 150 μM) plus different fixed con-
centrations of trastuzumab, cetuximab, erlotinib,
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ture plates. The concentrations of the anti-HER2 agents
were determined from dose-response experiments in
AU565 cells (data not shown). Agents were not renewed
during the entire period of cell exposure (48 h for erloti-
nib, gefitinib or lapatinib and 72 h for trastuzumab or
cetuximab), and control cells without agents were cul-
tured under the same conditions with comparable
media changes. Following treatment, the media was
replaced by drug-free medium (100 μL/well) containing
MTT solution (10 μL, 5 mg/ml in PBS), and incubation
was prolonged for 3 h at 37°C. After carefully removing
the supernatants, the formazan crystals formed by meta-
bolically viable cells were dissolved in DMSO (100 μL/
well) and the absorbance was determined at 570 nm in
a multi-well plate reader (Model Rosyf Anthos 2010,
Anthos Labtec B.V., Heerhugowaard, Nederland). Using
control optical density (OD) values (C), test OD values
(T), and time zero OD values (T0), the compound con-
centration that caused 50% growth inhibition (IC50
value) was calculated from the equation, 100 × ((T-
T0)/(C-T 0) )=5 0 .T h ed a t ap r e s e n t e da r ef r o mt h r e e
separate wells per assay and the assay was performed at
least three times.
Isobologram analysis of drug interactions
The interactions of G28UCM and EGCG with anti-HER
drugs (trastuzumab, lapatinib, gefitinib, erlotinib and
cetuximab) were evaluated by the isobologram method
as we have previously published [41,42]. Briefly, the con-
centration of one agent producing a 30% inhibitory
effect is plotted on the horizontal axis, and the concen-
tration of another agent producing the same degree of
effect is plotted on the vertical axis; a straight line join-
ing these two points represents zero interaction (addi-
tion) between two agents. The experimental isoeffect
points were the concentrations (expressed relative to the
IC30 concentrations) of the two agents that when com-
bined kill 30% of the cells. When the experimental isoef-
fect points fell below that line, the combination effect of
the two drugs was considered to be supra-additive or
synergistic, whereas antagonism occurs if the experi-
mental isoeffect points lie above it. Within the designed
assay range, a set of isoeffect points was generated
because there were multiple FASN inhibitors and anti-
target agent concentrations that achieved the same iso-
effect. A quantitative index of these interactions was
provided by the equation Ix = (A/a) + (B/b), where, for
this study, a and b represent the respective concentra-
tions of FASN inhibitors (EGCG or G28UCM) and anti-
HER agents (trastuzumab, cetuximab, erlotinib, gefitinib
and lapatinib) required to produce a fixed level of inhi-
bition (IC30)w h e na d m i n i s t e r e da l o n e ,a n dA and B
represent the concentrations required for the same
effect when the drugs were administered in combina-
tion, and Ix represents an index of drug interaction
(interaction index). Ix values of < 1 indicate synergy, a
value of 1 represents addition, and values of > 1 indicate
antagonism. For all estimations of Ix,w eu s e do n l yi s o -
bolos where intercept data for both axes were available.
Western blot analysis of tumour and cell lysates
Cells and animal tumour tissues were collected and
lysed in ice-cold lysis buffer containing 1 mM EDTA,
150 mM NaCl, 100 μg/mL PMSF, 50 mM Tris-HCl (pH
7.5), protease and phosphatase inhibitor cocktails
(Sigma). A sample was taken for measurement of pro-
tein content by Lowry-based BioRad assay (BioRad
Laboratories, Hercules, CA, USA) and either used
immediately or stored at -80°C. Total protein extracts
were immunoblotted using 3% to 8% SDS-PAGE
(FASN, p185
HER2/neu, phospho-p185
HER2/neu, mTOR and
phospho-mTOR) or 4% to 12% SDS-PAGE (AKT, phos-
pho-AKT, ERK1/2 and phospo-ERK1/2 and PARP),
transferred to nitrocellulose membranes and blocked for
1 h in blocking buffer at room temperature (2.5% pow-
dered-skim milk in PBS-T (10 mM Tris-HCL pH 8.0,
150 mM NaCl and 0.05% Tween-20)) to prevent non-
specific antibody binding. Blots were incubated over-
night at 4°C with the corresponding primary antibody
diluted in blocking buffer. After washes in PBS-T (3 × 5
minutes), blots were incubated for 1 h with the corre-
sponding secondary antibody and revealed, employing a
commercial kit (West Pico chemiluminescent substrate).
Blots were re-probed with an antibody for b-actin to
control for protein loading and transfer.
In vivo studies: human breast tumour xenograft
experiments
Experiments were conducted in accordance with guide-
lines on animal care and use established by Biomedical
Research Institute of Bellvitge (IDIBELL) Institutional
Animal Care and Scientific Committee. The BT474 cell
line was selected for the in vivo studies due to its high
constitutive FASN and HER2 expression and its in vivo
behavior, as we have previously reported [13]. A dose of
G28UCM of 40 mg/Kg was chosen for efficacy experi-
m e n t s .T e nf e m a l em i c ew e r ei n c l u d e di nt h ec o n t r o l
group and 14 in the G28UCM-treated group. Tumour
xenografts were established by subcutaneous injection of
10 × 10
6 BT474 cells mixed in Matrigel (BD Bioscience,
Bedford, MA, USA) into the flank. Tumours were
allowed to increase up to a size of 150 to 250 mm
3.
Mice were treated by intraperitoneal injection daily with
40 mg/Kg of G28UCM or vehicle for 45 days. Mice
were weighed once per week, tumours were measured
daily with electronic calipers, and tumour volumes were
calculated by the formula: (π/ 6×( v 1×v 2×v 2 ) ) ,w h e r e
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smallest one. At the end of the experiment, animals
were weighed and all mice were euthanized, and
tumours, brain, lung, heart, liver, spleen, intestine and
kidney tissues and serum were stored at -80°C.
In vivo studies: animal toxicity experiments
Experiments were conducted in accordance with guide-
lines on animal care and use established by Biomedical
Research Institute of Bellvitge (IDIBELL) Institutional
Animal Care and Cientific Committee (AAALAC unit
1155). The study protocol has received ethical approval.
F e m a l ea t h y m i cn u d eB A L B / cm i c e( f o u rt of i v ew e e k s
old, 23 to 25 g) were purchased from Harlan Labora-
tories (France), fed ad libitum with a standard rodent
chow and housed in a light/dark 12 h/12 h cycle at 22°C
i nap a t h o g e n - f r e ef a c i l i t yf o ro n ew e e k .A n i m a l sw e r e
randomized into four groups of six animals each: con-
t r o l ,5 ,4 0a n d7 5m g / K gG 28UCM-treated animals.
Each group received daily a single intraperitoneal (i.p.)
injection (0.5 mL) of G28UCM (5, 40 and 75 mg/Kg) or
vehicle alone (DMSO), dissolved in RPMI 1640 medium.
The body weight was registered daily for 45 days. On
day 45 animals were sacrified and renal (urea and creati-
nin) hepatic (aspartate transaminase, alanine trasaminase
and alkaline phosphatase) function markers, and hema-
tological parameters (% neutrophils, % lymphocytes, %
monocytes, % platelets, hemoglobine and % hematocrit)
were determined in serum of control and G28UCM-
treated animals.
Ex vivo immunohistochemistry of FASN
Immunohistochemical staining for FASN was performed
using a rabbit monoclonal antibody anti-FASN (Assay
Designs, Ann Arbor, MI, USA). Briefly, paraffin-
embedded tissue sections of control and G28UCM-trea-
ted xenografts were deparaffinized, rehydrated, and
blocked with 2% hydrogen peroxide for endogenous per-
oxidase. Slides were washed with phosphate-buffered
saline (PBS) and blocked with 20% horse serum (JRH
Bioscience, Lexena, KS, USA). Slides were then incu-
bated with anti-FASN antibody overnight at 4°C. After
additional PBS washes, sections were sequentially incu-
bated at room temperature for 45 minutes with biotin-
labeled antirabbit IgG (Envision + R System Labelled
Polymer-HRP anti-rabbit, Dako, Aachen, Germany).
Slides were washed with PBS and incubated with diami-
nobenzidine (DAB, Sigma Chemical, St. Louis, MO).
Finally, slides were counterstained with Hematoxylin-
eosin, dehydrated, cleared and cover-slipped. FASN
expression was categorized as negative (no or weak
expression) or positive (strong expression). Appropriate
positive and negative controls were included in each run
of immunohistochemistry. All immunohistochemically
stained slides were interpreted by a pathologist blinded
to other data.
Fluorescent in situ hibridation (FISH)
Cytospin slides of AU565 parental and resistant cells to
trastuzumab or lapatinib were prepared. The HER2
FISH pharmDX™ Kit (Dako, Aachen, Germany) was
used as directed by the manufacturer. Slides were heated
in Pre-Treatment Solution for 10 minutes, and digested
with ready-to-use pepsin at room temperature for 5 to
10 minutes. A ready-to-use FISH probe mix was hybri-
dised onto slides. This probe mix consists of a mixture
of Texas Red-labelled DNA probes covering a 218 kb
region including the HER2 gene on chromosome 17
(CEN17), and a mixture of fluorescein-labelled peptide
n u c l e i ca c i d( P N A )p r o b e st a r g e t e da tt h ec e n t r o m e r i c
region of CEN17. The specific hybridisation to the two
targets results in formation of a distinct red fluorescent
signal at each HER2 gene locus and a distinct green
fluorescent signal at each chromosome 17 centromere.
After a stringent wash with the buffer the slides were
mounted with fluorescent mounting medium containing
DAPI and coverslipped. Twenty nuclei were assessed for
HER2 and CEN17. The ratio of average HER2 to aver-
age CEN17 copy number was calculated. Gene amplifi-
cation was defined when the FISH ratio HER2 signal/
CEN17 signal was > 2.
Statistical analysis
R e s u l t sw e r ea n a l y s e db yS t u d e n t ’s t-test or by one-way
ANOVA using a Tukey test as a post-test. Statistical sig-
nificant levels were P <0 . 0 5( d e n o t e da s* )a n dP <
0.005 (denoted as**). All data are means ± standard
deviation (SD) or ± standard error (SE). All observations
were confirmed by at least three independent
experiments.
Results
Efficacy of G28UCM against breast carcinoma xenografts
Blocking FASN activity causes cytotoxicity in human
cancer cells overexpressing FASN [2-13]. The proposed
oncogenic properties of FASN seem to be the result of
an increased activation of HER2 and its downstream
related signaling pathway proteins [4,5,8,13-20]. Because
the in vitro studies were carried out for short-term peri-
ods, we further evaluated in vivo the long-term effect of
G28UCM, a novel pharmacological inhibitor of FASN.
BT474 human FASN+ and HER2+ breast carcinoma
xenografts served as the tumour target for the in vivo
studies. In all control animals, BT474 xenografts grew in
size, reaching volumes at day 45 which were from 50%
to 600% of the volumes at day 0 (first day of G28UCM
treatment). The median size of the tumours when the
experiments started was 127.4 ± 25.1 mm
3.I nt h e
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five cases, the xenografts experimented tumour volume
reductions ranging from -20% to -90% (10T, 11T, 12T,
13T and 14T, Figure 1A), while in nine cases tumour
growth was observed.
To analyse the activation of HER2 and its downstream
related phosphoinositide-3 kinase/protein kinase B
(PI3K/AKT) and mitogen-activated protein kinase/
extracellular signal-regulated kinase (MAPK/ERK1/2)
signalling cascades or to the mammalian target of rapa-
mycin protein (mTOR) signalling pathway, we per-
formed Western blotting and immunohistochemical
analysis of each individual animal tumour. Apoptosis
and induction of caspase activity were checked with
cleavage of poly-ADP-ribose polymerase (PARP) in
Western blotting analysis. Apoptosis was not detected in
Figure 1 G28UCM inhibits the growth of BT474 xenografts and do not induce weight loss in vivo. A. Daily i.p. 40 mg/Kg G28UCM-
treatment decreased tumour volume in a BT474 breast cancer xenograft (n = 14, grey bars) compared to vehicle control (n = 9, white bars). Five
G28UCM-treated animals exhibited no identifiable residual tumour at the end of the experiment (10T, 11T, 12T, 13T and 14T, grey bars). Data are
expressed as logarithm of percentage of individual tumour growth at day 45 respect to day 0. B. G28UCM-treated tumours showed apoptosis
and inactivation of HER2, ERK1/2 and mTOR signalling pathways, without affecting FASN protein expression levels. This figure only shows a
representative animal of each experimental group (4C -control-, 4T -treated no-responsive- and 12T -responsive-). All tumours were lysed and
equal amounts of protein were subjected to Western blot analyses with anti-PARP, anti-FASN, anti-HER2, anti-AKT, anti-ERK1/2 and anti-mTOR
antibodies. Activation of the protein under study was analysed by assessing the phosphorylation status using the corresponding phospho-
specific antibody. Blots were reprobed for b-actin as loading control. Gels shown are representative of those obtained from two independent
experiments. C. FASN expression level does not change between control and G28UCM-treated animals. Representative immunohistochemical
staining for FASN protein of xenograft tumour of untreated (4C) and G28UCM-treated non-responding (4T) and responding (12T) group. D.
G28UCM treatment does not induce weight loss. The body weight of each mouse was measured before and weekly after treatment with
G28UCM (40 mg/Kg/day for 45 days) or vehicle control. Data are expressed as percentage of initial body weight and represent mean values ± SE
for each experimental group.
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non-responding tumours. In contrast, in the tumours of
G28UCM- responding animals, there was an increase in
the levels of 89 kDa PARP product. Figure 1B shows the
results of some representative tumours of each experi-
mental group. We next examined the effects of
G28UCM on HER2 and its related downstream proteins
AKT, ERK1/2 and mTOR. Tumours that showed a
response to G28UCM had a marked decrease in phos-
phorylated HER2, ERK1/2 and mTOR proteins and, to a
lesser extent in phosphorylated AKT, without detectable
changes in the total levels of the corresponding proteins.
Figure 1B shows a representative result of each experi-
mental group.
We also analysed FASN protein expression levels of
each individual animal tumour. Results in Figure 1B
depict FASN levels from one representative animal of the
control group (4C, Figure 1A) and two G28UCM-treated
animals (4T and 12T, Figure 1A). No significant changes
in FASN protein levels were observed in any of the sam-
ples, as assessed both by Western blotting (Figure 1B)
and either by immunohistochemical staining (Figure 1C).
With respect to ex vivo FASN enzymatic activity (see
Additional file 1), however, the experimental tumours
that had a response to G28UCM (11T and 12T, Figure
1A) showed a decrease of 30.5 ± 15% compared with the
control 4C tumour (see Additional file 2).
Toxicity studies
Previous first-generations of FASN inhibitors have been
limited by inducing severe body weight loss, which is
thought to be related to a parallel stimulation of fatty
acid oxidation by these inhibitors [4,6,24-28]. To address
this problem, G28UCM were designed to inhibit FASN
activity without parallel stimulation of in vitro fatty acid
oxidation [13]. In this study, animals treated for 45 days
with G28UCM were weighed daily to evaluate in vivo
body weight effect of the novel FASN inhibitor. With
respect to control animals, we identified no significant
changes on food and fluid intake or body weight after
daily treatment with 40 mg/Kg of G28UCM for 45 days.
T h ea v e r a g ew e i g h to ft h ea n i m a l sa tt h eb e g i n n i n go f
the study was 19.8 ± 1.7 g. At the conclusion of the
study, control animals increased their weight by 7.15 ±
0.8% of pre-treatment weight, compared with 8.04 ±
1.6% for the G28UCM-treated animals (Figure 1D)
which was not statistically significant.
Hepatic and renal function serum markers (aspartate
transaminase, alanine transaminase, alkaline phospha-
tase, creatinin and urea) showed no significant alteration
between control and experimental animals treated with
G28UCM at daily doses of 5, 25 or 40 mg/Kg. Animals
treated at doses of 75 mg/Kg, however, showed differ-
ences compared with control in their blood counts, in
particular, increased neutrophils and platelet cells and
decreased monocytes and lymphocytes (see Additional
file 3 for hepatic, renal and hematological function
serum markers of G28UCM-treated animals). Histologi-
cal studies (Hematoxylin-Eosin, Masson’s Trichrome,
Sudan Black B and Picrosirius Red stains) of liver, heart,
kidney, lung and brain showed no tissue structural
abnormalities in G28UCM-treated animals when com-
pared with control animals (data not shown).
In vitro cell growth interactions between G28UCM and
anti-HER drugs
To determine how best to use G28UCM either as a sin-
gle agent or in combination with anti-HER drugs, we
conducted a series of in vitro studies to evaluate the
inhibitory effects of G28UCM in combination with tras-
tuzumab, cetuximab, erlotinib, gefitinib and lapatinib in
a pre-clinical model of HER2-overexpressing breast can-
cer cells. The combined effect was analysed by the iso-
bole method, using a series of isobologram
transformations of multiple dose-response curves at an
effect level of 30% (IC30), a type of analysis that we have
used previously [41,42]. Results in Table 1 show the
median interaction index (Ix) of combinations between
G28UCM with trastuzumab, cetuximab, erlotinib, gefiti-
nib and lapatinib. Simultaneous treatment of AU565
cells with G28UCM and either trastuzumab, lapatinib,
gefitinib or erlotinib resulted in a strong synergistic
interaction (Ix = 0.519 ± 0.178, Ix =0 . 7 9 6±0 . 1 4 4 ,
0.882, Ix =0 . 8 3 2±0 . 1 6 1a n dI x =0 . 7 3 5±0 . 0 9 2 ,
Table 1 Synergy analysis of the interaction between G28UCM and anti-HER drugs in AU565 cells
plus Anti-HER2 Anti-HER1
trastuzumab lapatinib gefitinib erlotinib cetuximab
G28UCM synergism
0.5 ± 0.2**
synergism
0.8 ± 0.1**
synergism
0.8 ± 0.2*
synergism
0.7 ± 0.1**
antagonism
1.9 ± 0.2**
EGCG additivism
1.1 ± 0.5
antagonism
1.9 ± 0.7*
antagonism
1.8 ± 0.7*
antagonism
1.4 ± 0.2*
antagonism
2.2 ± 0.2**
The interaction index (Ix) for the two-drug effect in AU565 cells was calculated using isobologram analysis. The Ix parameter indicate whether the doses of the
two drugs required to produce a given degree of cytotoxicity are greater than (Ix > 1 or antagonism) equal to (Ix = 1 or additivism) or less than (Ix <1o r
synergism) the doses that would be required if the effect of two agents were strictly additive. Ix values for the two drug treatment were obtained from triplicate
studies. * (P < 0.05) and ** (P < 0.005) indicate the level of statistical significance of the Ix compared with an Ix of 1.0.
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Page 6 of 13respectively). The combination of G28UCM plus cetuxi-
mab indicated a marked antagonistic interaction (Ix =
1.913 ± 0.243). Under the same schedule, EGCG showed
an additive interaction with trastuzumab (Ix =1 . 1 2 3±
0.458) and antagonistic interactions with lapatinib, gefi-
tinib and erlotinib and cetuximab (Ix =1 . 8 7 5±0 . 6 9 1 ,I x
=1 . 8 2 9±0 . 6 7 2 ,I x = 1.393 ± 0.229, Ix =2 . 1 5 6±0 . 2 1 5 ,
respectively). Together, these data show that co-expo-
sure of the FASN inhibitor G28UCM with drugs that
exhibit anti-HER2 activity (but not with the specific
anti-HER1 compound, cetuximab) is more active than
either of the drugs used alone.
Molecular interactions between G28UCM and anti-HER
drugs
To determine whether the molecular causes of the syner-
gistic interactions between G28UCM and trastuzumab,
lapatinib, cetuximab and erlotinib were triggered by
changes in the phosphorylated forms of HER2 and its
downstream signaling proteins, we analysed changes in
apoptosis and HER2, AKT and ERK1/2 protein phos-
phorylated forms. First, we studied the cell death
mechanism. Apoptosis and induction of caspase activity
were checked by Western blotting analysis showing clea-
vage of PARP. The experiments were done at a concen-
tration equal to the cytotoxicity IC50 value of G28UCM
and anti-HER drugs (trastuzumab, lapatinib, cetuximab
and erlotinib) in AU565 cells. Co-treatment of AU565
cells with G28UCM (30 μM) plus trastuzumab (1 μM)
during 24 h induced a marked increase in the levels of
the PARP cleavage product (89 kDa band) compared to
24 h single agent (G28UCM or trastuzumab) treatment
(Figure 2). The apoptotic effect of the combined regimes
was validated by flow cytometry using the Annexin V-
Alexa Fluor 488 staining (data not shown). Similar results
in PARP cleavage were obtained when AU565 cells were
co-treated with G28UCM (30 μM) plus lapatinib (5 μM)
during 12 hours or plus erlotinib (8 μM) during 24 hours
(Figure 2). Therefore, we sought to compare the effects
of combined treatments versus single drug treatments on
HER2, AKT, and ERK1/2 activation. The phosphorylated
form of HER2 (p-HER2) was noticeably decreased after
24 h exposure to G28UCM plus trastuzumab, and p-
AKT protein decreased after 48 h of co-treatment with
G28UCM and trastuzumab (Figure 3). Co-incubation of
cells with G28UCM and lapatinib was significantly corre-
lated with a decreased level of the phosphorylated form
of HER2 (pHER2) and p-ERK1/2, which occurred as
soon as 12 h after treatment compared to 12 h cell treat-
ment with either G28UCM or lapatinib alone (Figure 3).
Co-exposure of G28UCM plus erlotinib induced a
decrease of p-HER2 and p-AKT after 24 hours (Figure 3).
During all time-course co-treatment experiments no sig-
nificant change either in the total level of the correspond-
ing proteins (HER2, ERK1/2 and AKT) or in FASN levels
was detected (Figure 3).
As we expected, under the same culture conditions,
co-treatment of AU565 cells with G28UCM plus
Figure 2 G28UCM plus trastuzumab, lapatinib and erlotinib induced apoptosis in AU565 breast cancer cells. Induction of caspase
activity was confirmed by PARP cleavage. AU565 cells were treated with G28UCM (30 μM) plus trastuzumab (1 μM), lapatinib (5 μM), erlotinib (8
μM) or cetuximab (15 μg/ml) for 12 and 24 h (G28UCM plus lapatinib or erlotinib), and 24 and 48 h (G28UCM plus trastuzumab or cetuximab),
and equal amounts of lysates were immunoblotted with anti-PARP antibody which identified the 116 KDa (intact PARP) and the 89 KDa
(cleavage product) bands. Blots were reprobed for b-actin as loading control. Gels shown are representative of those obtained from two or three
independent experiments.
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Page 7 of 13Figure 3 G28UCM plus trastuzumab, lapatinib and erlotinib blocked the activation of HER2, AKT or ERK1/2 proteins. AU565 cells were
treated with G28UCM (30 μM) plus trastuzumab (1 μM), lapatinib (5 μM), erlotinib (8 μM) or cetuximab (15 μg/ml) for 12, 24, and 48 h, and
equal amounts of lysates were immunoblotted with anti-FASN, anti-HER2, anti- AKT, and anti-ERK1/2 antibodies. Activation of the protein under
study was analysed by assessing the phosphorylation status using the corresponding phospho-specific antibody. Blots were reprobed for b-actin
as loading control. Gels shown are representative of those obtained from two or three independent experiments.
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2 )a n dd i dn o tb l o c kH E R 2p h o s p h o r y l a t i o no ri t s
downstream related signal transduction pathways ERK1/
2 and PI3K/AKT (Figure 3).
Effect of G28UCM on cells resistant to trastuzumab or
lapatinib
The vast majority of HER2 positive advanced breast can-
cer patients develop resistance to trastuzumab based
therapies within the first year of treatment. Conse-
quently, identification of novel agents that inhibit the
growth of trastuzumab-resistant cells/tumours is critical
to improving the survival of metastatic HER2+ breast
cancer. For this purpose, we extended our study to
examine the anti-cancer effect of G28UCM on HER2+
breast cancer cells (AU565) that were continuously
exposed in culture medium supplemented with trastuzu-
mab (AU565TR) or lapatinib (AU565LR) over a period
of at least six months. Trastuzumab resistant
(AU565TR) or lapatinib resistant (AU565LR) cells were
developed in our laboratory as described in the Materi-
als and methods section. Sensitivity to trastuzumab was
determined by treating AU565 parental and resistant
cells to 2 μM trastuzumab and performing trypan blue
exclusion assay periodically during 10 days (Figure 4A,
left). A dose of 2 μM trastuzumab caused a significant
cell death in AU565 cells (70.2 ± 5%), but the majority
of AU565TR cells remained viable (94.6 ± 7%). Lapati-
nib resistance was confirmed by an MTT colorimetric
assay (Figure 4A, right).
To eliminate the possibility that we have selected a
population of resistant cells that do not possess HER2
gene amplification, we examined HER2 gene amplifica-
tion by fluorescence in situ hybridisation using a
method that determines oncogene copy number cor-
rected to the number of copies of chromosome 17
(CEP17). The ratio of the average HER2 gene copy
number to the average CEP17 gene copy number in
AU565TR was 3.9, 4.9 in AU565WT, and 4.4 in
AU565LR respectively, demonstrating that both trastu-
zumab and lapatinib resistant cells possess HER2 ampli-
fication similar as parental cells (Table 2).
Additionally, we performed immunoblotting experi-
ments to determine HER2, pospho-HER2 (pHER2) and
FASN protein levels in AU565TR and AU565LR cells.
HER2 and pHER2 were down-regulated in AU565TR
cells (Figure 4B). In AU565LR cells, protein levels of
HER2 and pHER2 did not change compared with
AU565WT cells and FASN levels were similar in the
three cell lines (Figure 4B). To analyse the sensitivity of
the resistant cells to G28UCM, we determined the
growth inhibition effect of this compound by an MTT
colorimetric assay, using trastuzumab and lapatinib as
reference compounds. As expected, trastuzumab and
lapatinib had either no effect or a weak effect on growth
inhibition of trastuzumab- and lapatinib-resistant cells,
respectively (Figure 4C). For instance, while the IC30
value of trastuzumab in AU565WT was 2 μM,
AU565TR cells were insensitive to trastuzumab at the
concentrations analysed (up to 50 μMo ft r a s t u z u m a b ) .
The IC30 value of lapatinib was increased from 1.6 μM
in AU565WT to 14 μM in AU565LR (Figure 4C). Tras-
tuzumab concentration necessary to achieve IC30 value
had to be increased about 16-fold in AU565LR (IC30 =
31.5 ± 4.9 μM) compared to AU565WT (IC30 =2±0 . 7
μM), and lapatinib had no cytotoxic activity in
AU565TR cells using doses up to 50 μM( F i g u r e4 C ) .
Interestingly, G28UCM showed similar cytotoxic activity
in parental (IC30 =2 2±7μM), trastuzumab- (IC30 =2 4
±8μM) and lapatinib-resistant cells (IC30 =1 7±2
μM). Taken together, these data suggest that inhibiting
FASN activity may be a new therapeutic strategy in
breast carcinomas with acquired resistance to anti-HER2
therapies.
Discussion
Treatment with G28UCM was associated with xenograft
volume reductions from 20% to 90%, in 5 of 14 animals.
The responding tumour tissues showed changes in
apoptosis and in HER2-related signalling pathways.
They showed an increase in the levels of 89 kDa PARP
product, and the phosphorylated forms of HER2
(pHER2), ERK1/2 (pERK1/2) and mTOR (pmTOR) were
almost abolished. These samples showed a decline in
FASN enzymatic activity, but not total FASN levels. It is
not clear why a substantial number of xenografts did
not respond to G28UCM. The degree of interindividual
variability in the response to G28UCM might be related
to bioavailability, clonal variation or experimental
design. Concerning bioavailability, G28UCM reached the
target tissue in the responding xenografts, since the in
vivo FASN inhibition was of 30% (see SD), which is
similar to the reported intra-tumour 40% inhibition of
FASN activity 12 hours after intraperitoneal injection of
other FASN inhibitors [43]. Non-responding tumours,
in contrast, had no detectable changes in apoptosis or
pHER2, pERK or pmTOR expression after treatment
with G28UCM. The observed inhibition was able to eli-
cit clear molecular responses in at least one-third of the
treated animals. Clonal variability of BT474 cells cannot
be excluded. In fact, Sheridan et al. described that 80%
of BT474 cells in culture expressed CD24, while 20%
did not [44]. The relevance of CD24, a cell adhesion
molecule, in our system is not clear. Furthermore, for
t h es a k eo ft h e r a p e u t i cs i g n ificance, our experimental
design consisted of administration of G28UCM after the
xenografts had reached a size of 100 to 150 mm
3.I ti s
possible that treating smaller tumours or administering
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Page 9 of 13G28UCM at the same time as the human cells might
translate into a less variable result. Future experiments
will need to explore in detail the pharmacokinetics and
pharmacodynamics of the compound in this model,
develop alternative animal and xenograft models, as well
as alternative routes of administration of the compound.
These in vivo data seem to confirm that the oncogenic
properties of FASN could be associated with an
increased phosphorylation of HER2, and its related
PI3K/AKT, MAPK/ERK1/2, and mTOR signaling
Figure 4 G28UCM shows cytotoxic activity in developed HER2 + and FASN + trastuzumab and lapatinib-resistant cells. A. Development
of trastuzumab- and lapatinib-resistant AU565-derived cells. AU565 parental cells (with ○) and AU565 cells cultured for six months in 2 μMo f
trastuzumab (AU565TR, with ●) were both treated with 2 μM of trastuzumab for 2, 3, 6, 8 and 10 days. Cells were trypsinized and counted by
trypan blue exclusion. Results are shown as the percentages of viable cells compared with untreated control cultures for each cell line and
period-time. All experiments were repeated at least two times. AU565 parental cells (with ○) and AU565 cells cultured for one month in 3.5 μM
and the next five months in 7 μM of lapatinib (AU565LR, with ●) were both treated in with different concentrations of lapatinib (1 to 10 μM) for
48 h. Circles represent the percentage of surviving cells after 48 h in lapatinib treatment, which was determined using an MTT assay. Results are
expressed as percentage of surviving cells from three independent experiments performed in triplicate (mean ± SD). B. FASN and HER2
expression levels in parental and resistant cells. AU565 parental and resistant cells (AU565TR and AU565LR) were lysed for protein and
immunoblotted for FASN, T-HER2, p-HER2. Blots were reprobed for b-actin as loading control. Gels shown are representative of those obtained
from three independent experiments. C. Cytotoxicity in AU565 parental and resistant cells (AU565TR and AU565LR) following G28UCM treatment.
AU565 parental and resistant cells were treated along with different concentrations of G28UCM (1 to 40 μM), trastuzumab (1 to 50 μM) or
lapatinib (1 to 50 μM). Results represent IC30 values of G28UCM, trastuzumab and lapatinib in AU565 parental and resistant cells (AU565TR and
AU565LR), which was determined using an MTT assay. Results are expressed as mean IC30 values ± SD from three independent experiments
performed in triplicate.
Table 2 FISH* analysis of HER2 gene copy number in AU565WT, AU565TR and AU565LR cells
CELL LINES AU565WT AU565TR AU565LR
Ratio of average HER2 to average CEN17 gene copy number
† 4.9 3.9 4.4
AU565WT, AU565 Wild Type; AU565TR, AU565 cells resistant to trastuzumab; AU565LR, AU565 cells resistant to lapatinib;
* FISH, fluorescence in situ hybridisation;
† HER2/CEN17 > 2 indicates HER2 gene amplification.
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Page 10 of 13cascades [4,5,8,13-20]. In this report we did not address
the issue of the extent to which the effects of G28UCM
are mediated by inhibition of FASN alone or by off-tar-
g e te f f e c t s ,s i n c ew eh a v er e p o r t e dp r e v i o u s l yo nt h i s
relationship [13]. Future experiments, however, will
address the specificity of G28UCM against FASN. This
is particularly important since the parent molecule of
G28UCM has been reported to have an array of biologi-
cal activities, including the inhibition of gelatinase-B
(MMP-2), NO synthase or aromatase enzymatic activ-
ities [45-47].
An important part of our in vivo results concerns the
toxicity of G28UCM. We performed a long-term weight
evaluation, and no significant effect on food and fluid
intake or body weight was identified after daily treat-
ment with 40 mg/Kg of G28UCM for 45 days. In addi-
tion, hepatic and renal function serum markers and
histological studies of liver, heart, kidney, lung and brain
showed no significant alterations between control and
animals treated during 45 days with daily G28UCM. We
suggest that the chemical structure of G28UCM may be
more specific of the lipogenic pathway than cerulenin or
its derivatives, which stimulate CPT-1 and accelerate
fatty acid b-oxidation, which has been related to the
severe decrease of food intake and induction of weight
loss in rodents [24-28].
We found that the simultaneous treatment of FASN
+/HER2+ breast cancer cells with G28UCM plus trastu-
zumab or lapatinib (which involve predominantly
HER2), resulted in a strong synergistic interaction, and
that this was also observed with gefitinib or erlotinib
(inhibitors of HER1 but also HER2 tyrosine kinase activ-
ities) [48,49]. In contrast, the combination of G28UCM
with the monoclonal antibody cetuximab (which is
HER1-specific) resulted in an antagonistic effect. Taken
together, these results support that the interactions
between FASN and HER proteins are restricted to
HER2 and do not involve the HER1 receptor. On the
other hand, EGCG showed only an additive interaction
with trastuzumab and an antagonistic interaction with
lapatinib, gefitinib, erlotinib and cetuximab, which may
be in part related to the lower cytotoxic activity of
EGCG by itself. We also addressed the molecular inter-
actions of G28UCM, analysing FASN protein levels,
apoptosis, and the phosphorylated forms of HER2, AKT
and ERK1/2 proteins after G28UCM combined with
trastuzumab, erlotinib, gefitinib or lapatinib treatment.
Trastuzumab and HER tyrosine kinase inhibitors (lapati-
nib, gefitinib and erlotinib) displayed molecular synergis-
tic interaction with G28UCM. This synergistic effect was
accompanied by increased apoptosis and seemed to be
mediated by abrogation of the activation of HER2, AKT
and ERK1/2 when the drugs are combined. It is impor-
tant that the synergistic molecular effects observed with
G28UCM in combination with trastuzumab, erlotinib,
gefitinib or lapatinib followed the same pattern than the
cellular effects. These in vitro cellular and molecular
synergistic results support the in vivo evaluation of
these agents in a combination regimen.
F i n a l l y ,w eu s e ds t a b l ec e l ll i n e sd e r i v e df r o mt h e
AU565 cells that were resistant to either trastuzumab
(AU565TR) or lapatinib (AU565LR) to test the antican-
cer properties of G28UCM. In these cells, in which the
cytotoxicity of trastuzumab and lapatinib were almost
lost, we observed that the cytotoxic activity of G28UCM
in the resistant cells and in the parental cells was simi-
lar. The activity of G28UCM in this model of resistance
to anti-HER2 treatments is consistent with a previous
report that observed that trastuzumab-resistant breast
cancer cells were sensitive to EGCG [50]. Furthermore,
our results also show that, even after long-term expo-
sure to trastuzumab and lapatinib, resistant cells contin-
ued to overexpress FASN.
Conclusions
In summary, our findings provide a rationale for the
pre-clinical development of G28UCM either alone or in
combination with anti-HER agents (trastuzumab, lapati-
nib, erlotinib, gefitinib or cetuximab) in HER2-overex-
pressing breast cancer. In addition, we report the effect
of G28UCM on breast cancer cells resistant to trastuzu-
mab or lapatinib. Our data support the study of
G28UCM as a potential therapeutic agent, either alone
or in combination, against in vivo HER2+ tumours that
have progressed on trastuzumab and lapatinib. Future
studies will focus on testing the in vivo activity of
G28UCM in mice bearing trastuzumab and lapatinib
resistant xenografts.
Additional material
Additional file 1: Additional Material and methods on ex vivo FASN
enzymatic activity assay.
Additional file 2: Figure. FASN activity decrease in G28UCM-treated
responsive animal. Twelve hours after the last i.p. G28UCM injection,
tumour tissues from a representative animal of control (4C) and
G28UCM-treated responding group (12T) were minced and
homogenized in ice-cold lysis buffer and FASN activity was assayed in
particle-free supernatants by recording spectrophotometrically at 37°C
the decrease of A340 nm due to oxidation of NADPH after the addition
of malonyl-CoA as described in the Materials and methods section. Data
are mean ± SD from two separate experiments.
Additional file 3: Table. Hepatic, renal and hematological function
serum markers of G28UCM-treated animals.
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